We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings

By LabMedica International staff writers
Posted on 15 Jul 2025

The high cost and logistical complexities associated with rapid, point-of-care tests have long hampered widespread access to molecular diagnostics, especially in low- and middle-income countries. More...

In these settings, the need for accurate and affordable pathogen detection is particularly pressing, especially during outbreaks. Traditional diagnostic methods often rely on expensive tests, require cold chains for transport and storage, and demand sophisticated laboratory setups, making them difficult to deploy in resource-limited environments. Researchers have now developed a new, more affordable solution aimed at addressing these issues, making molecular diagnostics more accessible and feasible in underserved areas.

A team from the Vienna BioCenter (Vienna, Austria) and the West African Center for Cell Biology of Infectious Pathogens (WACCBIP) at the University of Ghana (Accra, Ghana) has developed a lyophilized open-source reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for pathogen detection. This assay uses non-proprietary enzymes, including reverse transcriptase, DNA polymerase, and uracil DNA glycosylase, to reduce reliance on expensive commercial solutions. The assay is both heat-stable and robust, making it possible to store and transport the diagnostic tools at ambient or elevated temperatures, bypassing the need for cold chains. The RT-LAMP assay is adaptable for rapid detection of various pathogens and can be used with swab or gargle samples, demonstrating high sensitivity and providing a colorimetric result. The open-source nature of the assay means that the enzyme mixture can be self-produced, further driving down costs and improving accessibility.

The assay was tested in a proof-of-concept study with lyophilized RT-LAMP reaction mixes shipped to Ghana, where it showed performance comparable to results obtained in Vienna. This study, published in Life Science Alliance, demonstrated that the assay is both robust and suitable for field implementation across diverse settings. The researchers envision multiple models for implementation, ranging from centralized production to decentralized in-lab preparation. The team is working to make the assay more widely accessible, having deposited essential vectors and providing protocols for protein expression and purification on publicly accessible platforms. Moving forward, the researchers plan to further validate the system's performance across a broader range of pathogens and settings.

“By making reliable pathogen detection both affordable and independent of complex logistics like cold chains, our protocols empower laboratories and public health institutions worldwide to take control of their diagnostic capabilities, especially during outbreaks,” said co-first author Martin Matl, PhD.

Related Links:
Vienna BioCenter
WACCBIP


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
All-in-One Molecular System
AIO M160
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.